Hepatic Metastasectomy Colon Cancer India: Cost and Guide|
Hepatic metastasectomy for colon cancer in India costs USD 7,000–12,000 all-in. 20–30% five-year survival in selected patients. JCI hospitals.
Hepatic Metastasectomy for Colon Cancer in India: A Complete, Honest Guide for International Patients
When colon cancer spreads to the liver, most patients are told the disease is incurable. For a significant minority of those patients, that verdict is wrong. Surgery to remove liver metastases — hepatic metastasectomy — offers 20 to 30 percent five-year survival in carefully selected patients. That is not hope dressed up as statistics. That is genuine long-term cure in roughly one in four patients who qualify for and undergo the operation.
This guide is written for patients who have been told their colon cancer has spread to the liver and who want to understand whether surgery is an option for them, what the operation involves, what the recovery looks like, what the honest survival data shows, and why India has some of the best hepatobiliary surgical teams in the world at a fraction of Western cost. The most important section is the one on patient selection — because the surgery only works when it is done in the right patients, by the right surgeons, at the right volume centres.
Hepatic metastasectomy for colorectal liver metastases in India — surgical removal of liver tumours with 20 to 30 percent five-year survival in selected patients — at 85 percent lower cost than the United States at specialist hepatobiliary centres.
- 1Who qualifies for liver surgery — the five criteria that matter
- 2What hepatic metastasectomy involves — step by step
- 3The role of chemotherapy — before and after liver surgery
- 4Simultaneous colon and liver surgery — when and why
- 5Borderline resectable disease — when chemotherapy makes surgery possible
- 6What hepatic metastasectomy costs in India vs the world
- 7Which hospitals in India perform this at sufficient volume
- 8Survival data — honest numbers from published studies
- 9How to get a resectability assessment as an international patient
Yes — for selected patients. Hepatic metastasectomy for colorectal liver metastases achieves five-year survival of 20 to 30 percent in patients where complete resection is achievable — representing genuine long-term cure. India's highest-volume hepatobiliary centres, including Medanta The Medicity and Tata Memorial Hospital, perform this operation at volumes that match specialist centres in the United States and Europe. The all-in surgical cost is USD 7,000 to 12,000 in India — compared to USD 50,000 to 90,000 in the USA. The resectability assessment — determining whether you are a surgical candidate — can be done from your existing imaging without you travelling first.
Who Qualifies for Liver Surgery — The Five Criteria That Matter
The question every patient with colorectal liver metastases asks first is: am I a candidate for surgery? The answer requires assessment against five specific criteria. Meeting all five is not always necessary — modern surgical thinking has moved away from rigid numerical rules toward a more nuanced evaluation based on the complete clinical picture. But these five criteria frame the conversation and guide the decision.
Complete resection is achievable
All liver metastases must be removable with clear surgical margins — no tumour cells at the cut edge of the resected liver tissue. Leaving positive margins defeats the purpose of surgery and does not improve survival over chemotherapy alone. This is a non-negotiable requirement.
Adequate future liver remnant
After removing the tumour-bearing liver tissue, at least 25 to 30 percent of total functional liver volume must remain. In patients who have received prolonged chemotherapy — which can damage the liver — a higher remnant volume of 30 to 40 percent is required. The future liver remnant is calculated from the CT scan using volumetric software.
No unresectable extrahepatic disease
Disease outside the liver must either be absent or itself resectable. Patients with limited lung metastases that can also be surgically removed may still be candidates. Patients with extensive peritoneal disease, bone metastases, or brain involvement are generally not surgical candidates for hepatic metastasectomy — though some are candidates for HIPEC if the disease is confined to the peritoneum.
Primary colon tumour controlled
The source of the liver metastases — the primary colon tumour — must either have already been removed or be removable in the same or a staged operation. Hepatic metastasectomy without addressing the primary tumour is performed occasionally when the primary is asymptomatic and systemic chemotherapy controls both sites, but this is not standard practice.
Adequate patient fitness for major surgery
Hepatic metastasectomy is major abdominal surgery. Patients need adequate cardiac, pulmonary, and renal reserve to withstand the operation and the post-operative period. Performance status — how active and functional the patient is day-to-day — is assessed and must be adequate. Patients with significant comorbidities are not automatically excluded, but their overall risk is higher and must be weighed against the potential benefit.
Historically, having more than three or four liver metastases was considered a contraindication to surgery. Modern surgical evidence has moved well beyond this rule. Published series include patients with six, eight, or even ten liver lesions who have undergone complete resection and achieved long-term survival. What matters is not the count — it is whether complete resection with clear margins is achievable while preserving adequate functional liver volume. Patients told they have "too many" tumours for surgery should seek a formal second opinion from a high-volume hepatobiliary centre before accepting that verdict.
Get a formal resectability assessment from your existing imaging
Send your most recent CT scan of the chest, abdomen, and pelvis and your staging information to GAF Healthcare. A hepatobiliary surgical oncologist at Medanta or Tata Memorial will provide a written resectability assessment — including whether surgery is indicated, what type of resection would be required, and an itemised cost estimate — within 48 to 72 hours.
Request Resectability Assessment →What Hepatic Metastasectomy Involves — Step by Step
Hepatic metastasectomy is the surgical removal of liver tumour deposits. The term covers a range of operations from a minor wedge resection removing a small peripheral tumour under 30 minutes, to a major hepatectomy removing five or six of the liver's eight segments over several hours. Understanding the range of what is possible helps patients appreciate that liver surgery is not a single procedure — it is a highly individualised operation whose complexity depends entirely on the number, size, and position of the tumours.
Pre-operative planning — the most important 48 hours
Before any incision, the hepatobiliary surgeon spends a significant amount of time studying your imaging. A high-quality contrast-enhanced CT scan or MRI of the liver — performed with specific liver protocol sequences — is essential. The surgeon maps every tumour: its location within the liver's anatomical segments, its relationship to the major hepatic veins, the portal vein branches, and the bile ducts, and the amount of healthy liver volume in each segment. This three-dimensional mental model of the tumour-liver anatomy determines the surgical strategy — which tumours will be removed, which hepatic segments will be sacrificed, what the future liver remnant volume will be, and whether the operation is feasible in a single stage.
At India's top hepatobiliary centres, this planning process is performed in a formal multidisciplinary tumour board that includes the hepatobiliary surgeon, a radiologist specialised in liver imaging, a medical oncologist, and a hepatologist. The tumour board reviews the imaging, discusses the chemotherapy history and its effect on liver function, and agrees the surgical plan before the patient is booked for the operating list.
Types of hepatic resection
The liver has eight anatomically distinct segments, each with its own blood supply and bile drainage. Hepatic resections are classified anatomically: a wedge resection removes a small rim of liver around a superficial tumour without respecting anatomical segment boundaries. A segmentectomy removes one or two anatomical segments along their natural boundaries. A right hemihepatectomy removes segments 5, 6, 7, and 8 — the right lobe. A left hemihepatectomy removes segments 2, 3, and 4. An extended right hepatectomy adds segment 4 to the right lobe removal, leaving only segments 2 and 3 as the future liver remnant.
The guiding principle — regardless of which type of resection is performed — is: remove all tumour with clear margins while preserving the maximum possible volume of functional liver tissue. This principle sometimes means performing a complex, anatomically irregular resection that maximises preservation of healthy liver rather than a straightforward anatomical hemihepatectomy that would remove too much normal tissue.
Laparoscopic versus open liver resection
Laparoscopic liver resection — performing the hepatectomy through small keyhole incisions — is technically feasible for tumours in accessible liver segments and has become standard practice at high-volume hepatobiliary centres worldwide. The advantages over open hepatectomy are the same as in colon surgery: less blood loss, less post-operative pain, shorter hospital stay, and faster recovery. India's leading hepatobiliary centres at Medanta, Apollo, and Fortis perform laparoscopic liver resection for suitable tumour locations — typically segments 2, 3, 4b, 5, and 6 — while major right hepatectomies and extended resections typically require an open approach to achieve adequate exposure and safety.
Robotic-assisted liver resection is also available at select Indian centres — Apollo Chennai and Medanta Gurgaon — for specific indications. The clinical evidence for robotic over laparoscopic liver resection is less established than for colorectal surgery, and the additional cost premium is higher. For most hepatic metastasectomy patients, laparoscopic resection where feasible, or open resection for more complex cases, remains the standard approach.
Intraoperative ultrasound — finding what scans miss
One of the most important components of hepatic metastasectomy — and one that distinguishes high-volume specialist centres from lower-volume units — is the routine use of intraoperative ultrasound. During surgery, before any liver tissue is cut, the surgeon places an ultrasound probe directly on the liver surface and performs a systematic scan of all eight segments. This intraoperative ultrasound detects tumour deposits that were not visible on pre-operative CT or MRI — typically small lesions under 1 centimetre in diameter. Finding these additional deposits changes the surgical plan in approximately 15 to 20 percent of cases — sometimes making the surgery more extensive than planned, sometimes revealing deposits in locations that make complete resection impossible. Either way, the intraoperative ultrasound prevents the surgeon from completing an operation that would leave disease behind unknowingly.
Ask: "Do you routinely perform intraoperative ultrasound during hepatic metastasectomy?" A surgeon who does not routinely use intraoperative ultrasound is operating with incomplete information about what is in the liver. Also ask: "How many hepatic metastasectomies for colorectal cancer do you perform per year personally?" The target is 30 or more per year for the individual surgeon. GAF Healthcare obtains both answers in writing before making any hepatic metastasectomy referral.
The Role of Chemotherapy — Before and After Liver Surgery
The relationship between chemotherapy and surgery for colorectal liver metastases is not a simple either-or decision — in most cases, both are used, and the sequence matters. Understanding when chemotherapy comes before surgery, when it comes after, and why prolonged pre-operative chemotherapy can actually be harmful helps patients engage more meaningfully in treatment planning conversations.
Perioperative chemotherapy — the EPOC approach
The standard approach for patients with resectable colorectal liver metastases — established by the EPOC trial — is perioperative chemotherapy: three cycles of FOLFOX before surgery, surgery, then three cycles of FOLFOX after surgery. The pre-operative chemotherapy shrinks the tumours and makes resection technically easier. More importantly, it tests whether the cancer responds to FOLFOX — patients whose tumours continue to grow on pre-operative FOLFOX have a poor prognosis regardless of surgery, and the chemotherapy response reveals this information before a major operation is performed. The post-operative chemotherapy addresses microscopic systemic deposits that surgery cannot reach. The EPOC trial demonstrated a 25 percent improvement in progression-free survival with this approach compared to surgery alone.
One nuance of the EPOC approach that has become clearer since the trial: the pre-operative chemotherapy must not be given for too long. Extended pre-operative chemotherapy — eight or more cycles before surgery — causes hepatotoxicity, damages the normal liver parenchyma, and reduces the functional reserve of the liver tissue that will remain after surgery. FOLFOX causes a condition called chemotherapy-associated steatohepatitis, and bevacizumab can impair wound healing after surgery. Most hepatobiliary surgeons recommend no more than three to four cycles of FOLFOX before liver resection — enough to assess response and downsize tumours, not enough to compromise the liver's functional capacity.
Surgery first — when to skip pre-operative chemotherapy
For patients presenting with clearly resectable liver metastases — particularly when the number of tumours is small, the lesions are peripheral, and the future liver remnant is clearly adequate — some surgeons advocate proceeding directly to surgery without pre-operative chemotherapy. This approach preserves the liver's full functional reserve for the surgical recovery, avoids chemotherapy toxicity before a major operation, and simplifies the treatment timeline. The post-operative chemotherapy course — six cycles of FOLFOX after surgery — provides the systemic treatment component.
There is no single correct answer to the pre-operative chemotherapy question for resectable disease — it is a clinical judgment based on the specific patient's tumour characteristics, liver volume calculations, comorbidities, and the surgeon's assessment of resectability confidence. At India's top hepatobiliary centres, this decision is made at the multidisciplinary tumour board, not by a single surgeon's preference.
Already on chemotherapy and wondering about liver surgery?
Send your current treatment details, most recent CT scan, and staging to GAF Healthcare. A hepatobiliary surgeon at Medanta or Tata Memorial will review whether liver surgery is indicated at this point in your treatment — including whether you have received too many chemotherapy cycles before surgery and need to proceed to the operating room now. Written assessment within 48 hours.
Simultaneous Colon and Liver Surgery — When and Why
Some patients with synchronous colorectal liver metastases — meaning the liver disease is diagnosed at the same time as the primary colon cancer, rather than appearing later — are candidates for simultaneous resection: removing the primary colon tumour and the liver metastases in the same anaesthetic and the same operating session. This approach has significant practical advantages for international patients — one operation instead of two, one hospital admission, one recovery period, one visa application, one set of flights. For patients from Africa or the Gulf who are making a significant journey to access high-quality surgical care, avoiding a second trip to India several months later is practically meaningful.
The suitability of simultaneous resection depends on the complexity of each component. When the colon resection is laparoscopic and straightforward — for example a laparoscopic right hemicolectomy combined with a minor peripheral liver resection — simultaneous surgery typically adds only 45 to 90 minutes to the operating time and carries a similar safety profile to either operation alone. When either component is major — an extensive hepatectomy combined with a complex low anterior rectal resection, for example — the combination places significant physiological stress on the patient and staged surgery is generally safer.
At Medanta The Medicity and Tata Memorial Hospital, dedicated combined colorectal-hepatobiliary surgical teams perform simultaneous colon and liver resection routinely for selected patients. The colorectal surgical oncologist and the hepatobiliary surgeon operate together, each working in their area of expertise, with the sequence — usually colon resection first, then liver resection — planned to minimise total anaesthetic time and blood loss. GAF Healthcare specifically asks each hospital whether simultaneous resection is offered and whether the two surgical teams have an established working relationship for combined cases.
| Approach | India cost | When appropriate |
|---|---|---|
| Hepatic metastasectomy only (primary already removed) | $7,000 – $12,000 | Primary colon cancer already removed previously. Metachronous metastases appearing after initial surgery. |
| Simultaneous colon + liver resection | $10,000 – $18,000 | Synchronous disease. Both components are of moderate complexity. One operating session. |
| Staged: colon first, liver after 6–8 weeks | $4,500–$6,500 + $7,000–$12,000 | Either component is extensive. Symptomatic primary — obstruction or bleeding — must be addressed first. |
| Liver first approach | $7,000–$12,000 + $4,500–$6,500 | Liver metastases are more immediately threatening. Primary is asymptomatic and can wait. Chemotherapy bridges the interval. |
Sources: GAF Healthcare Hospital Cost Database 2026 · Medanta, Tata Memorial, Fortis international patient tariffs · Simultaneous resection literature: Reddy et al. Annals of Surgery 2007
Borderline Resectable Disease — When Chemotherapy Makes Surgery Possible
One of the most clinically important categories in colorectal liver metastases is borderline resectable disease — tumours that cannot be removed safely at initial presentation but might become resectable after chemotherapy shrinks them. This category is important because it represents patients who are currently being told surgery is not possible but who may become surgical candidates with the right treatment sequence.
The conversion rate — the proportion of patients with initially unresectable liver metastases who become resectable after chemotherapy — ranges from 12 to 35 percent depending on the chemotherapy regimen used and the quality of initial resectability assessment. For patients with initially unresectable disease who respond to chemotherapy and achieve downstaging to resectable, subsequent hepatic metastasectomy offers survival outcomes approaching those seen in patients who were resectable from the outset — with some series reporting five-year survival rates of 15 to 25 percent in converted patients.
The most important message for patients with currently unresectable liver metastases: do not accept that surgery will never be an option without reassessment after chemotherapy response. After three to four cycles of FOLFOX or FOLFOX plus cetuximab — the regimen with the highest response rate for RAS wild-type left-sided disease — repeat imaging should formally reassess resectability. The reassessment should be done by a hepatobiliary surgeon, not by a medical oncologist, because the surgical judgment of what is and is not resectable is inherently a surgical skill.
For patients where the tumour is resectable but the future liver remnant volume is too small — below 25 percent — a procedure called portal vein embolisation can be performed 4 to 6 weeks before surgery to stimulate growth of the future remnant. By blocking blood flow to the tumour-bearing lobe, the procedure redirects portal blood flow to the planned remnant, causing it to hypertrophy by 30 to 50 percent in size over the following weeks. This technique — available at Tata Memorial and Medanta — converts some patients from technically unresectable due to insufficient remnant volume to surgical candidates. India's cost for portal vein embolisation is USD 2,500 to 4,000, compared to USD 15,000 to 25,000 in the United States.
What Hepatic Metastasectomy Costs in India vs the World
The costs below are based on 2026 tariff data from GAF Healthcare's partner hospitals. The hepatic metastasectomy package covers specific components — understanding what is and is not included prevents unexpected billing.
| Component | India | USA | Notes |
|---|---|---|---|
| Pre-operative staging CT + MRI liver protocol | $600 – $1,000 | $8,000 – $15,000 | Before surgery |
| Minor hepatic resection (wedge / segmentectomy) | $7,000 – $9,000 | $50,000 – $70,000 | 1–3 lesions, peripheral |
| Major hepatectomy (hemihepatectomy) | $9,000 – $14,000 | $65,000 – $100,000 | Right or left lobe removal |
| Extended hepatectomy (5+ segments) | $11,000 – $16,000 | $80,000 – $120,000 | Complex bilateral disease |
| Simultaneous colon + liver (combined) | $10,000 – $18,000 | $100,000 – $180,000 | One anaesthetic, two teams |
| Portal vein embolisation (if needed) | $2,500 – $4,000 | $15,000 – $25,000 | When remnant too small |
| FOLFOX adjuvant — 6 cycles (post-op) | $1,500 – $2,800 | $12,000 – $25,000 | Starts 6–8 weeks post-op |
Sources: GAF Healthcare Hospital Cost Database 2026 · Medanta, Tata Memorial, Apollo, Fortis hepatobiliary tariffs · CMS Hospital Price Transparency Data USA 2026 · NHS Private Patient Tariff 2025
"I was told in the UAE that my three liver metastases were inoperable because they were close to the hepatic vein. Medanta reviewed my CT and their hepatobiliary surgeon said two were easily resectable and the third could be addressed with radiofrequency ablation at the same session. The combined procedure cost USD 9,800 all-in. Three years later I am clear."
Full itemised cost reference for the complete colorectal cancer treatment pathway including hepatic metastasectomy, HIPEC, chemotherapy, and targeted therapy — with honest country-by-country comparisons.
Get an itemised cost estimate for your liver surgery
Cost varies significantly based on the extent of resection required, whether portal vein embolisation is needed, and whether simultaneous colon surgery is indicated. Send your CT scan and GAF Healthcare will provide an itemised estimate within 48 hours.
Get My Cost Estimate →Which Hospitals in India Perform Hepatic Metastasectomy at Sufficient Volume
Hepatic metastasectomy requires a specialist hepatobiliary surgical oncologist — not a general surgeon, not even a general surgical oncologist. The procedure demands anatomical knowledge of the liver's complex segmental architecture, intraoperative ultrasound skill, the ability to control major hepatic vessels during resection, and the judgment to know when a tumour that appeared resectable on imaging is not safely removable at surgery. This expertise is concentrated at a small number of Indian centres.
Medanta The Medicity, Gurgaon — India's strongest private hepatobiliary programme
Medanta's Institute of Digestive and Hepatobiliary Sciences is, in GAF Healthcare's assessment, India's strongest private-sector hepatobiliary surgical programme for colorectal liver metastases. The hepatobiliary surgical team performs over 200 liver resections per year — a volume that places it in the highest tier globally. The team has specific experience with simultaneous colon and liver resection, portal vein embolisation, and the two-stage liver resection strategy for bilateral disease. For international patients, Medanta's dedicated international patient floor and 20-minute proximity to IGI Airport make the logistics significantly easier.
Tata Memorial Hospital, Mumbai — Highest overall volume for complex cases
Tata Memorial Hospital's surgical oncology team includes senior hepatobiliary surgeons who perform hepatic metastasectomy at high volume as part of a broader colorectal oncology programme that sees 800 to 1,000 new colorectal cases per year. For patients with complex bilateral disease, borderline resectable metastases requiring neoadjuvant chemotherapy and portal vein embolisation, or disease that has been refused at other centres, Tata Memorial's depth of expertise and tumour board review process is unmatched in India. The government hospital environment means lower cost than private alternatives — and no compromise on clinical quality.
Apollo Hospitals, Chennai — Strongest laparoscopic liver programme
Apollo Chennai has a dedicated hepatobiliary surgical oncology team with significant laparoscopic liver resection experience — one of the most active laparoscopic liver programmes in India. For patients with tumours in accessible liver segments where laparoscopic resection is feasible — offering faster recovery and shorter hospital stay — Apollo Chennai provides the strongest laparoscopic hepatobiliary programme among India's JCI-accredited private hospitals. The full Apollo international patient infrastructure — 24-hour English-speaking coordinators, integrated accommodation support, proton therapy on the same campus for select cases — makes it particularly practical for patients from the UK, East Africa, and Southeast Asia.
Fortis Memorial Research Institute, Gurgaon — Best for Gulf and Africa combined cases
Fortis Memorial's hepatobiliary programme is part of an integrated GI oncology team that handles simultaneous colon and liver resection, with dedicated colorectal and hepatobiliary surgical oncologists who work together regularly for combined cases. For international patients from Africa and the Gulf who need both colon and liver surgery and want it handled in one admission at a JCI-accredited centre with strong international patient infrastructure, Fortis is a strong second option to Medanta in the Delhi-NCR region.
Independent ranking of eight hospitals based on colorectal and hepatobiliary surgical volume, combined resection capability, molecular diagnostics, and international patient infrastructure.
Survival Data — Honest Numbers from Published Studies
The survival data for hepatic metastasectomy for colorectal cancer is among the most studied in oncology — more than three decades of published series from Europe, the United States, and Asia. The overall picture is consistent: complete resection offers a meaningful chance of long-term survival that no systemic chemotherapy regimen can replicate, and the prognostic factors that predict better outcomes are well-established.
| Clinical scenario | Survival outcome | Source | Key factor |
|---|---|---|---|
| Complete resection (R0) — all series | 5-yr OS: 25–35% | Multiple registry series | R0 resection achieved |
| Solitary liver metastasis — R0 resection | 5-yr OS: 40–50% | Fong et al. Annals Surgery 1999 | Single lesion, best prognosis |
| EPOC trial — perioperative FOLFOX + surgery | PFS improved 25% | Nordlinger et al. Lancet 2008 | Surgery + periop chemo |
| Converted unresectable — post-chemo surgery | 5-yr OS: 15–25% | Adam et al. Annals Surgery 2004 | Chemo response then surgery |
| 4+ metastases — complete resection achieved | 5-yr OS: 15–22% | LiverMetSurvey Registry | More disease, still beneficial |
| Chemotherapy only — no surgery | Median OS 20–30 months | Multiple Stage 4 chemo trials | No surgery possible |
| Positive resection margin (R1) | 5-yr OS: 5–10% | Multiple series | Incomplete resection — poor outcome |
Sources: Fong Y et al. (Annals of Surgery 1999) · Nordlinger B et al. EPOC trial (Lancet 2008) · Adam R et al. (Annals of Surgery 2004) · LiverMetSurvey European Registry · SEER Database 2024
The last two rows of the table carry the most important messages. Positive resection margin — R1 — produces outcomes almost as poor as chemotherapy alone, reinforcing that complete resection is the non-negotiable requirement and that operating with the primary goal of achieving an R0 margin is central to the decision of whether to operate at all. And chemotherapy alone — for patients who never become surgical candidates — still produces meaningful disease control, with modern regimens achieving median overall survival of 24 to 30 months in Stage 4 colon cancer patients with liver-only metastases who receive chemotherapy without surgery.
The Clinical Risk Score — developed by Fong and colleagues at Memorial Sloan Kettering — predicts post-surgical survival based on five factors: node-positive primary colon cancer, disease-free interval less than 12 months, more than one liver metastasis, largest metastasis above 5 centimetres, and CEA above 200. Each factor scores one point. A CRS of 0 to 2 is associated with five-year survival above 40 percent. A CRS of 5 is associated with five-year survival below 15 percent. The CRS does not disqualify anyone from surgery — it helps set realistic expectations and guides the intensity of perioperative chemotherapy.
How to Get a Resectability Assessment as an International Patient
The resectability assessment — the formal surgical opinion on whether your liver metastases can be safely removed — can be done from your existing imaging before you travel. This is the most important first step, and it is one you can take this week.
-
1
Send the right imaging — CT and MRI of the liver
The most important imaging for hepatic metastasectomy assessment is a high-quality contrast-enhanced CT of the chest, abdomen, and pelvis plus — ideally — an MRI of the liver with dedicated liver protocol sequences. The MRI provides superior characterisation of liver tumour margins and relationship to vessels. Send these as DICOM files along with your pathology report, CEA result, and molecular profiling results.
-
2
Receive resectability assessment and surgical plan within 72 hours
GAF Healthcare forwards your imaging to a hepatobiliary surgical oncologist at Medanta and Tata Memorial simultaneously. You receive two written resectability assessments — including whether surgery is feasible, what type of resection is planned, whether portal vein embolisation is needed, whether simultaneous colon surgery is indicated, and itemised cost estimates. Comparing two independent surgical opinions gives you a complete picture.
-
3
Pre-operative chemotherapy if indicated — coordinated with India team
If the surgical team recommends three to four cycles of pre-operative FOLFOX before surgery, GAF Healthcare coordinates with your local oncologist to start chemotherapy while the India admission is planned. The surgical date is booked for approximately 4 to 6 weeks after chemotherapy completion, allowing adequate liver recovery time.
-
4
Arrival and final pre-operative assessment
Airport transfer arranged. Within 24 to 48 hours, the hospital performs repeat staging CT, liver MRI, cardiac and pulmonary assessment, and blood tests including liver function. The hepatobiliary tumour board performs a final pre-operative review. Surgery is scheduled within 5 to 7 days of this assessment.
-
5
Hepatic metastasectomy — 1 to 5 hours depending on extent
Surgery under general anaesthesia. Intraoperative ultrasound performed systematically before any resection. Resection carried out with margin clearance as the primary objective. ICU for 1 to 2 days post-operatively. Ward stay 5 to 8 days. Pathology — confirming R0 margin and histological characteristics — available within 7 days of surgery.
-
6
Fly home with complete post-operative and adjuvant protocol
Discharge package includes the operative report, liver histopathology with margin status, adjuvant FOLFOX protocol for your local oncologist, liver function recovery monitoring schedule, and covering letter. Most patients fly home 25 to 35 days after arrival. Adjuvant chemotherapy begins 6 to 8 weeks post-operatively — started in India or continued at home with the discharge protocol.
Being told surgery is not possible is not always the final answer.
Send your most recent CT and MRI, staging information, and pathology. Within 48 to 72 hours you will have written resectability assessments from two hepatobiliary surgical oncologists — one at Medanta, one at Tata Memorial — with their independent opinions on whether liver surgery is feasible for your case. Free. No obligation.